Innovation and imitation,opportunity an₩σd challenge
Asia-Pacific Pharma IP Leader summit2019---®✘ε14th-15th NOV, Beijing CHINAOn March 19, 2019,↑÷λ the World Intellectual Property Organization (W•πIPO) published its global intellectual properδ←××ty report 2018.Asian★↔ innovators filed more tha₽✔n half of their internationa±φl patent applications thro&£ugh WIPO for the first time in 2018, with →£↕ significant growth in China, India and©™÷ South Korea, the report noted. ↕λAs a technology-intensive indusδ®try, pharmaceutical indust∞↓ry attaches great importance to pa•δφ®tent application and intellectual property pπ÷rotection.In recent years,₩φ'€ the size of the global pharmaceutical ∏©market has maintained a steady growth, wit₩←γ↑h China, South Korea, India and o✘ther emerging markets pr£∞™esenting a rapid growth momentum. ★λ♥;Due to the different intelle→&ctual property policies of differ₩≥>ent countries, the strategic lay☆↑×out of global intellectual property, the diffe£∏&rences of pharmaceutical γ✘☆intellectual property policie≈φα≠s of Asia-pacific countries, the patent revi≠←λ±ew process, litigation procedur™ es and Generic drug patent strategy have graduaφ₽lly become the hot spots of★↓→ the pharmaceutical intellectual property indus←€∏±try.In this context, the 2019 Asia-pacifδ♣∞φic Pharmaceutical IP Leader Summit wβ±>ill be held in Beijing on November 14-1®♦×5, and will attract more than 500 industrγ↕"≈y experts from domest∏ ' ic and foreign pharmaceutical companies, biotec✘ &hnology companies, governments, associat₹€↕©ions, law firms, intellectual prop↕πerty agents and other companies to attend.Age ≤nda Framework:Section 1:Int¶↑←erpretation of Policy: Development of Pharmace ↑☆utical IP under the New Legislaδ$↕tive Landscape Section 2:Pharmaceutical R&ε××D Innovation and IP Protection -'₩- Global VisionSection 3:Ca ππse Sharing of Pharmaceutica¥&∑&l Patent Invalidity, Infringement ↔$↑, LitigationSection 4:Opportunities×♣ and challenges for generics c•∞σompanies under the new situλγation HOTSPOT:ü&n₩δ₹♣bsp; Medical Policy Interpretation under ₹₹♠the Background of Pa•$tent Law Amendmentü ©§; The innovation of Judicial Mechanism Promo→×☆tes the Development of Pharm♦aceutical Intellectu∑≠'al Propertyü InΩβ←"tellectual Property Man≈♠♦agement Experience in Mul↓♥♦tinational Pharmaceutical Companies, Pa¶↓εtent Layout Strategy, Litigation S↕$₹trategyü he Data Protectiשon Regulations of Drug Test—New Eraü&nbs p; Trade Secrets and Patent Layo≥δλut in the Medical Fieldü Establi≤♠shing The Internal Inte♣€llectual Property Sy♠¥€±stem under The New Legislati₩>☆ve Landscapeü Opportunities and Chal÷≠✘lenges of Pharmaceutical Enterpris'×≥es under Patent Term Compensation Syst¶£em--- Global Vision aε≥≥nd Its Implications for Chinaü >¥® Latest Changes in European Patent ¥π♠∞Application and Revi→&ew Proceduresü ↓<>Analysis of Hot Cases of Recent Patent ✘✘≈Invalidationü The Proce•♣₩↑dure of American Pharmaceutical Patent litigat≤₹₩↕ion and its Enlightenment to Chinese Pharmaceuti♥§™cal Enterprises ü Applicatio✘≈n techniques and protection §$↕strategies for European and American biomedical p≈★>÷atentsü Changes inπ↕∑₩ standards for creative review o↔•f patentsü European, American and Japa→£nese Medical Patent Examination "✘Cases and its implications for Domγ♦♦esticPharmaceutical <↑αCompaniesü Recent Hot Patent Inf£←ringement Cases Analysisü ≥'∞; The Strategy of Indian Generic Drug±σ € Companies in R&D and Pre-PAü≥♣ How to avoid the Pate↕←₩₹nt Trap in Generic Drug Developmentü Ωλ; The Strategy of Generic Druδβ↕g Companies to Enter the European an ★↔σd American Marketsü Patε€δ entability in Europe, the United States and Chi↓∞®≠naü Patent litigation in Europeü&n☆±εbsp; Doubts around the Uni ₹ δfied Patent Court (UPC) agreement and Brexitü&nb♥αsp; Second medical use p≥¥ΩatentsComposition of par♣☆↑ticipants: Su₹ mmit highlights:10+ H$δot topic20+ Auth&☆oritative speech5 0+ Industry med©♦πia4 0+ BIC110+pharma c≤ε©™ompany 500+專業(yè)參會(huì)嘉賓&nb→≥×♥sp; &n∞σ₽bsp; &nb≥γsp; Professional participantsOfficial reg₩₩∑≈istration and consultation ₩α✔channels:Contact:AnnPhone: 021-65650305Email:Mark♣Ωeting@zenseegroup.comhttp://en.zenseeg'roup.com/p/510934/